- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Divi's Laboratories Limited — Important, 03-02-2025: Financial Result Updates
**Consolidated Financials:**
Divi’s Laboratories reported a consolidated total income of ₹2401 crores for the quarter and ₹7041 crores for the nine months ending December 31, 2024. This marks a strong growth of approximately 23% year-over-year for the quarter, driven by increased demand and operational efficiencies in the pharmaceutical sector. The profit before tax (PBT) for the quarter stood at ₹726 crores, up from ₹489 crores in the same quarter last year. For the nine-month period, PBT rose to ₹2052 crores from ₹1450 crores.
**Profit and EPS:**
Net profit for the quarter amounted to ₹589 crores, reflecting a robust increase from ₹358 crores YoY, translating to earnings per share (EPS) of ₹22.20. For the nine-month period, net profit reached ₹1529 crores, compared to ₹1062 crores in the previous year.
**Operational Costs:**
Total expenses for Q3 were ₹1675 crores, up from ₹1461 crores YoY, with significant increases noted in employee benefits (11% increase) and other operational costs. These rising costs indicate enhanced staffing and strategic investments, but the controlled rise suggests effective cost management.
**Balance Sheet & Cash Flow Statement:**
The company maintains a strong balance sheet, with a paid-up equity capital of ₹53 crores and substantial other equity of ₹13518 crores, indicating solid retained earnings. Recent capital expenditures related to operations in Kakinada, valued at ₹557 crores over nine months, further bolster growth prospects.
**Strategic Position and Outlook:**
With the Kakinada Project's commercial operations commencing, the company is well-positioned for continued growth. Emphasis on expanding production capabilities highlights a focus on increasing market share.
**Investor Insight:**
Considering the impressive growth metrics, effective cost management, and ongoing expansion, a 'buy' stance is advised, as Divi’s Laboratories is likely poised for sustained performance amid a growing pharmaceutical market.